[go: up one dir, main page]

WO2009031635A1 - Vecteur recombinant utilise dans le traitement du diabete insipide nephrogenique et utilisation associee - Google Patents

Vecteur recombinant utilise dans le traitement du diabete insipide nephrogenique et utilisation associee Download PDF

Info

Publication number
WO2009031635A1
WO2009031635A1 PCT/JP2008/066034 JP2008066034W WO2009031635A1 WO 2009031635 A1 WO2009031635 A1 WO 2009031635A1 JP 2008066034 W JP2008066034 W JP 2008066034W WO 2009031635 A1 WO2009031635 A1 WO 2009031635A1
Authority
WO
WIPO (PCT)
Prior art keywords
diabetes insipidus
treatment
nephrogenic diabetes
recombinant vector
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/066034
Other languages
English (en)
Japanese (ja)
Inventor
Hiroshi Nagasaki
Hidetaka Suga
Yutaka Oiso
Mamoru Hasegawa
Makoto Inoue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nagoya University NUC
Original Assignee
Nagoya University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nagoya University NUC filed Critical Nagoya University NUC
Publication of WO2009031635A1 publication Critical patent/WO2009031635A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18841—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une nouvelle méthode de traitement du diabète insipide néphrogénique. L'invention concerne également un vecteur recombinant destiné à être utilisé dans le traitement du diabète insipide néphrogénique, ledit vecteur portant un gène d'aquaporine-2. Dans un mode de réalisation préféré, un vecteur du virus Sendai sert de vecteur.
PCT/JP2008/066034 2007-09-07 2008-09-05 Vecteur recombinant utilise dans le traitement du diabete insipide nephrogenique et utilisation associee Ceased WO2009031635A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-232310 2007-09-07
JP2007232310 2007-09-07

Publications (1)

Publication Number Publication Date
WO2009031635A1 true WO2009031635A1 (fr) 2009-03-12

Family

ID=40428947

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/066034 Ceased WO2009031635A1 (fr) 2007-09-07 2008-09-05 Vecteur recombinant utilise dans le traitement du diabete insipide nephrogenique et utilisation associee

Country Status (2)

Country Link
JP (1) JP2009079042A (fr)
WO (1) WO2009031635A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021043340A3 (fr) * 2019-09-05 2021-04-22 南京安吉生物科技有限公司 Protéine aquaporine 2 de marqueur tumoral et son application

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2564900C2 (ru) * 2010-03-10 2015-10-10 Дзе Юниверсити Оф Флорида Рисерч Фаундейшн, Инк. Модулирование аквапоринов релаксином
JP6402667B2 (ja) * 2015-03-27 2018-10-10 株式会社豊田中央研究所 生体適合性液体及びそのスクリーニング方法
CN109266616A (zh) * 2018-08-21 2019-01-25 山西省人民医院 一种稳定表达aqp2蛋白的人源化小鼠足细胞模型及其构建方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000264A1 (fr) * 2000-06-27 2002-01-03 Dnavec Research Inc. Vecteur de virus pour transfert de gene dans des cellules renales

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000264A1 (fr) * 2000-06-27 2002-01-03 Dnavec Research Inc. Vecteur de virus pour transfert de gene dans des cellules renales

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
HIROSHI ARIMA ET AL.: "Nyohosho Chiryo no Tenbo", SAISHIN IGAKU, vol. 57, no. 12, 2002, pages 2694 - 2699 *
KATSURA, T. ET AL.: "Constitutive and regulated membrane expression of aquaporin 1 and aquaporin 2 water channels in stably transfected LLC- PK 1 epitherial cells", PROC. NATL. ACAD. SCI. USA, vol. 92, 1995, pages 7212 - 7216, XP055354079 *
SUGA, H. ET AL.: "Novel treatment for lithium induced nephrogenic diabetes insipidus rat model using the sendai-virus vector carrying aquaporin 2 gene", ENDOCRINOLOGY, 24 July 2008 (2008-07-24), Retrieved from the Internet <URL:http://endo. endojournals.org/cgi/rapidpdf/en.2007-1806v1> [retrieved on 20081027] *
VERKMAN, A.S. ET AL.: "Aquaporin gene delivery to kidney", KIDNEY INT., vol. 61, 2002, pages S-120 - S-124 *
YANG, B. ET AL.: "Neonatal mortality in an aquaporin-2 knock-in mouse model of recessive nephrogenic diabetes insipidus", J. BIOL. CHEM., vol. 276, no. 4, 26 January 2001 (2001-01-26), pages 2775 - 2779, XP055354074 *
YUTAKA OISO: "Idensei Nyohosho Hassho ni Kansuru Bunshi Kiko", IGAKU NO AYUMI, vol. 213, no. 5, 30 April 2005 (2005-04-30), pages 342 - 346 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021043340A3 (fr) * 2019-09-05 2021-04-22 南京安吉生物科技有限公司 Protéine aquaporine 2 de marqueur tumoral et son application

Also Published As

Publication number Publication date
JP2009079042A (ja) 2009-04-16

Similar Documents

Publication Publication Date Title
WO2010120514A3 (fr) Protéines liant des antigènes comprenant des échafaudages protéiniques internes recombinants
AU2010327993A8 (en) 4-oxo-1H-quinoline-3-carboxamides as modulators of ATP-Binding cassette transporters
SG195194A1 (en) Nanogels
WO2012045082A3 (fr) Synthèse d&#39;acides nucléiques et méthodes d&#39;utilisation associées
WO2012170911A3 (fr) Vecteurs de thérapie génique pour l&#39;adrénoleucodystrophie et l&#39;adrénomyéloneuropathie
EP2273975B8 (fr) Solutions pharmaceutiques, procédé de préparation et utilisations thérapeutiques
WO2010068862A3 (fr) Polymères zwitterioniques présentant des fractions thérapeutiques
EP2315833B8 (fr) Vecteurs pour la délivrance de protéines photosensibles et procédés d&#39;utilisation
CA2818990A1 (fr) Proteines de repetition concues se liant a l&#39;albumine serique
EP2614418A4 (fr) Procédé de fonctionnement d&#39;un dispositif mobile basé sur la reconnaissance d&#39;un geste de l&#39;utilisateur et dispositif mobile utilisant ce procédé
NZ616989A (en) Therapeutic nuclease compositions and methods
NZ603623A (en) Tcr complex immunotherapeutics
JP2014501492A5 (fr)
WO2010022195A3 (fr) Système de vecteur hybride à base de virus non-intégratif et de virus adéno-associé
WO2012083302A3 (fr) Compositions et procédés pour le traitement ou la prévention d&#39;une infection par l&#39;adénovirus 36 humain
AP3277A (en) Gene encoding human glucokinase mutant, enzyme encoded by the same, recombinant vectors and hosts, pharmaceutical compositions and uses thereof, methods for treating and preventing diseases
WO2007106022A3 (fr) Nouvelles formes cristallines
WO2013036622A3 (fr) Peptides antiviraux efficaces contre le virus de l&#39;hépatite c
WO2009031635A1 (fr) Vecteur recombinant utilise dans le traitement du diabete insipide nephrogenique et utilisation associee
WO2013006692A3 (fr) Méthodes de traitement utilisant un pentapeptide dérivé de l&#39;extrémité c-terminale du glp-1 (glucagon-like peptide 1)
WO2009111336A3 (fr) Procédés pour purifier de l&#39;adn plasmidique
WO2012010976A3 (fr) Variants de méganucléases clivant une séquence d&#39;adn cible dans le gène tert et leurs utilisations
WO2011051916A3 (fr) Formulations de protéine stabilisées et utilisation correspondante
WO2007019865A3 (fr) Traitement au moyen de peptides de liaison cd4 et par rayonnements
NZ599521A (en) Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08829025

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08829025

Country of ref document: EP

Kind code of ref document: A1